# Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

> **NCT02978222** · PHASE2 · TERMINATED · sponsor: **Marker Therapeutics, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** FRα peptide plus Adjuvant (GM-CSF)
- **DRUG:** Adjuvant (GM-CSF) Alone

## Key facts

- **NCT ID:** NCT02978222
- **Lead sponsor:** Marker Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-20
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** Futility analysis did not support continuation of the trial
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978222, "Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02978222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*